Axovant (AXGT) to Offer Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Axovant Gene Therapies Announces Commencement of Public Offering
February 19, 2020 4:02 PM ESTNEW YORK and BASEL, Switzerland, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced that it has commenced an underwritten public offering of its common shares and pre-funded warrants to purchase its common shares. In connection with this offering, Axovant expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the aggregate number of common shares plus the common shares underlying the pre-funded warrants in the offering on the same terms and conditions. All of the common shares and pre-funded warrants are... More



